KALA BIO, Inc. (NASDAQ:KALA) said it expects to launch its first commercial artificial intelligence product in about two weeks, according to a company press release.
The firm said the product will be part of its new platform, Researgency.ai, which is designed to deploy AI agents for biotechnology and pharmaceutical companies. The announcement comes as KALA BIO trades with a market capitalization of roughly $8.3 million, with shares recently around $0.29 after falling about 96% over the past year.
According to the company, its scientific team is collaborating with engineers from Younet to develop the first customized AI agent, which is expected to be delivered by late March. The Researgency.ai platform is already operational and available to enterprise customers.
“Our first agent ships in 14 days, and our team is fired up,” said Avi Minkowitz.
The platform is designed to support several workflows common in biotech and pharmaceutical organizations, including research intelligence, clinical trial documentation, regulatory compliance, safety monitoring and preparation for commercial product launches. The AI agents will run in a secure environment designed to meet pharmaceutical industry compliance standards.
KALA BIO said it is pursuing a dual strategy that combines development of its proprietary biologics pipeline with the AI platform business. The company’s drug development portfolio includes a mesenchymal stem cell secretome platform and product candidates that have received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration. The company also holds an exclusive global license for the Researgency AI research platform from Younet.
The company’s shift toward artificial intelligence comes as it faces financial pressure. KALA BIO currently reports a current ratio of about 0.75, indicating its short-term liabilities exceed its liquid assets.
The company did not disclose pricing for the platform, the specific workflow that the first AI agent will address or details regarding any existing customer agreements. Market projections cited by the company estimate that the global AI healthcare market could surpass $180 billion by 2030.
KALA BIO said it plans to provide further details about the first AI agent after launch, including the specific use case it targets and how the product’s value will be measured.
In separate developments, KALA BIO recently reached a settlement with Oxford Finance LLC resolving approximately $10.6 million in debt obligations. The company made a $2 million payment that fully satisfied its commitments under a previous loan agreement and addressed earlier default events.
The company has also announced a strategic initiative to develop an on-premises artificial intelligence infrastructure platform for the biotechnology sector in partnership with Younet AI.
Additionally, KALA BIO’s Audit Committee approved the dismissal of Deloitte & Touche LLP as the company’s independent registered public accounting firm, although a replacement auditor has not yet been named.
KALA BIO has scheduled its next annual meeting of shareholders for January 30, 2026, with further details expected to be included in a forthcoming proxy statement.